VWM
CPRX

Vermillion Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Vermillion Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100
Closed -$2.48K – 1738
2026
Q1 		$2.48K Hold
100
– – ﹤0.01% 612
2025
Q4 		$2.33K Sell
100
-26
-21% -$579 ﹤0.01% 509
2025
Q3 		$2.48K Buy
126
+26
+26% +$535 ﹤0.01% 1369
2025
Q2 		$2.17K Hold
100
– – ﹤0.01% 447
2025
Q1 		$2.42K Hold
100
– – ﹤0.01% 1170
2024
Q4 		$2.09K Buy
+100
New +$2.15K ﹤0.01% 445

Other funds holding CPRX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
OLA
Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Vermillion Wealth Management's CPRX Position: Q2 2026 in Review

Vermillion Wealth Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 100 shares — an estimated $2.48K sold.

Vermillion Wealth Management first reported a position in CPRX in Q4 2024 and held it in 6 quarters. The position peaked at $2.48K in Q3 2025. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Vermillion Wealth Management reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Vermillion Wealth Management sold 100 Catalyst Pharmaceutical shares in Q2 2026, an estimated $2.48K.
  • Vermillion Wealth Management first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 6 quarters.
  • Vermillion Wealth Management's Catalyst Pharmaceutical position peaked at $2.48K in Q3 2025.
  • 36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.